Gastric pentadecapeptide BPC-157 researched for pleiotropic regenerative signaling via VEGFR2, GHR sensitization, and NO homeostasis
Price range: $34.00 through $89.00
| Quantity | Discounted Price |
|---|---|
| 3 - 5 | $32.30 |
| 6 - 8 | $31.62 |
| 9 + | $30.60 |
BPC-157 is an experimental pentadecapeptide, a synthetic fragment derived from an endogenous protein found in mammalian gastric juice. Preclinical analysis indicates it does not function through a single, high-affinity receptor but rather acts as a pleiotropic regulator, modulating a complex network of signaling pathways integral to tissue repair, cytoprotection, and the systemic response to injury.
The observed effects of BPC-157 stem from key pathway modulations documented in preclinical models:
Rigorous, large-scale, randomized controlled trials (RCTs) necessary to establish definitive efficacy and safety are critically lacking, resulting in an overwhelming reliance on preclinical animal models. The limited human studies reported in the literature are primarily small-scale and/or unpublished, and their results are considered anecdotal and scientifically unproven.
| Study/Trial Type | Compound Measured | Objective/Setting | Key Observed Outcomes |
|---|---|---|---|
| Retrospective Study | BPC-157 (Intra-articular injection) | Small, retrospective evaluation involving 16 subjects with unspecified chronic knee pain. | 14 out of 16 subjects reported subjective pain relief that was sustained for over six months. |
| Phase II Trial | BPC-157 (PL 14736, administered via enema) | Investigated in rats with active ulcerative colitis (a subtype of Inflammatory Bowel Disease). | Results reportedly indicated safety and efficacy in inducing remission. Full, peer-reviewed data remains unavailable. |
| Pilot Study | BPC-157 (Intravesical injection) | Investigated in 12 subjects diagnosed with interstitial cystitis. | Reportedly led to symptom resolution in a majority of the participants. |
| Phase I Trial | BPC-157 (Oral tablet formulation) | Registered on ClinicalTrials.gov (NCT02637284) as a phase I clinical trial in healthy volunteers to study safety and pharmacokinetics of BPC-157, a pentadecapeptide from gastric source. | No results have been posted or published. The status of this trial is unclear. |
BPC-157 exhibits characteristics that represent a significant divergence from typical therapeutic peptides, primarily concerning its stability and unique pharmacological mechanism, as highlighted by preclinical analysis.
| Feature | BPC-157 (Gastric Pentadecapeptide) | Conventional Therapeutic Peptides (Generally) |
|---|---|---|
| Physicochemical Stability | Demonstrates exceptional resilience; highly resistant to enzymatic degradation and hydrolysis, remaining intact in acidic environments. | Typically fragile and rapidly degraded by proteases in the digestive system and bloodstream. |
| Delivery Consideration | High stability allows for the possibility of oral research administration while still achieving systemic effects. | Poor oral bioavailability, generally necessitating parenteral (injection) administration to bypass the gastrointestinal tract. |
| Pharmacological Action | Acts as a biological “trigger” or initiator; brief exposure is sufficient to activate sustained downstream cellular processes (e.g., upregulating receptor gene expression). | Rapidly cleared, generally only interacting with fast-acting cell surface receptors, often requiring continuous presence. |
The products offered by Modern Aminos are intended strictly for laboratory research purposes only and are sold exclusively to qualified professionals, institutions, and entities. These products are not for human consumption, veterinary use, or any other application involving living organisms, including but not limited to diagnostic, therapeutic, or recreational purposes.
By purchasing this product, you confirm that:
Modern Aminos does not claim that this product is approved by the U.S. Food and Drug Administration (FDA) for any purpose. The statements regarding this product have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
The buyer assumes full responsibility for ensuring the safe handling, storage, and use of this product. Modern Aminos is not liable for any damages, direct or indirect, resulting from improper handling, storage, or unauthorized use of this product. Furthermore, Modern Aminos reserves the right to refuse sales to any individual or entity suspected of misusing its products.
If you have questions about the safe and lawful use of this product, consult a qualified professional with expertise in laboratory research. By proceeding with this purchase, you agree to these terms and conditions.
